Raymond M. Jordt
Known title: Chief Business OfficerCIK: 0001960780
Associated companies
Transaction History
| ALT | ▲ Buy | Grant | 4,571 | $14K | 1/31/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 15,850 | $0 | 1/27/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 4,229 | $26K | 1/27/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 14,600 | $0 | 1/25/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,855 | $21K | 1/25/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,375 | $0 | 1/1/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,475 | $9K | 1/1/2026 | View on chart |
| ALT | ▲ Buy | Grant | 1,368 | $4K | 7/31/2025 | View on chart |
| ALT | ▲ Buy | Grant | 2,614 | $14K | 1/31/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 14,600 | $0 | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,862 | $27K | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,485 | $18K | 1/1/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,375 | $0 | 1/1/2025 | View on chart |
| ALT | ▲ Buy | Grant | 917 | $5K | 7/31/2024 | View on chart |
| ALT | ▲ Buy | Grant | 5,030 | $14K | 1/31/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,375 | $0 | 1/1/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,503 | $28K | 1/1/2024 | View on chart |
| ALT | ▲ Buy | Grant | 1,832 | $5K | 7/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.